CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: January 29, 2016
Result type: Reports
Project Number: SR0478-000
Product Line: Reimbursement Review

Generic Name: Apremilast

Brand Name: Otezla

Manufacturer: Celgene

Therapeutic Area: Psoriasis, moderate to severe plaque

Indications: Psoriasis, moderate to severe plaque

Submission Type: Resubmission

Project Status: Complete

Date Recommendation Issued: October 26, 2016

Recommendation Type: Reimburse with clinical criteria and/or conditions